Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 29 entries
Sorted by: Best Match Show Resources per page
The role of entecavir in the treatment of chronic hepatitis B.

Therapeutics and clinical risk management

Dimou E, Papadimitropoulos V, Hadziyannis SJ.
PMID: 18516259
Ther Clin Risk Manag. 2007 Dec;3(6):1077-86.

Entecavir (ETV) is a potent and selective inhibitor of hepatitis B virus replication. In HBeAg-positive and HBeAg-negative lamivudine-naïve patients with chronic hepatitis B (CHB), treatment with ETV at a dose of 0.5 mg daily is associated with a more...

Cite
Dimou E, Papadimitropoulos V, Hadziyannis SJ. The role of entecavir in the treatment of chronic hepatitis B. Ther Clin Risk Manag. 2007;3(6):1077-86
Dimou, E., Papadimitropoulos, V., & Hadziyannis, S. J. (2007). The role of entecavir in the treatment of chronic hepatitis B. Therapeutics and clinical risk management, 3(6), 1077-86.
Dimou, Evangelini, et al. "The role of entecavir in the treatment of chronic hepatitis B." Therapeutics and clinical risk management vol. 3,6 (2007): 1077-86.
Dimou E, Papadimitropoulos V, Hadziyannis SJ. The role of entecavir in the treatment of chronic hepatitis B. Ther Clin Risk Manag. 2007 Dec;3(6):1077-86. PMID: 18516259; PMCID: PMC2387288.
Copy Download .nbib Format: NLM
Differences in epidemiology, liver disease and treatment response among HCV genotypes.

Hepatology research : the official journal of the Japan Society of Hepatology

Hadziyannis SJ, Koskinas JS.
PMID: 15203075
Hepatol Res. 2004 Jul;29(3):129-135. doi: 10.1016/j.hepres.2004.02.011.

No abstract available.

Cite
Hadziyannis SJ, Koskinas JS. Differences in epidemiology, liver disease and treatment response among HCV genotypes. Hepatol Res. 2004;29(3):129-135doi: 10.1016/j.hepres.2004.02.011.
Hadziyannis, S. J., & Koskinas, J. S. (2004). Differences in epidemiology, liver disease and treatment response among HCV genotypes. Hepatology research : the official journal of the Japan Society of Hepatology, 29(3), 129-135. https://doi.org/10.1016/j.hepres.2004.02.011
Hadziyannis, Stephanos J., and Koskinas, John S.. "Differences in epidemiology, liver disease and treatment response among HCV genotypes." Hepatology research : the official journal of the Japan Society of Hepatology vol. 29,3 (2004): 129-135. doi: https://doi.org/10.1016/j.hepres.2004.02.011
Hadziyannis SJ, Koskinas JS. Differences in epidemiology, liver disease and treatment response among HCV genotypes. Hepatol Res. 2004 Jul;29(3):129-135. doi: 10.1016/j.hepres.2004.02.011. PMID: 15203075.
Copy Download .nbib Format: NLM
Acute rhabdomyolysis following quail consumption.

Annals of Saudi medicine

Papanikolaou IS, Dourakis SP, Papadimitropoulos VS, Hadziyannis SJ.
PMID: 17264558
Ann Saudi Med. 2001 May-Jul;21(3):219-20. doi: 10.5144/0256-4947.2001.219.

No abstract available.

Cite
Papanikolaou IS, Dourakis SP, Papadimitropoulos VS, et al. Acute rhabdomyolysis following quail consumption. Ann Saudi Med. 2001;21(3):219-20doi: 10.5144/0256-4947.2001.219.
Papanikolaou, I. S., Dourakis, S. P., Papadimitropoulos, V. S., & Hadziyannis, S. J. (2001). Acute rhabdomyolysis following quail consumption. Annals of Saudi medicine, 21(3), 219-20. https://doi.org/10.5144/0256-4947.2001.219
Papanikolaou, I S, et al. "Acute rhabdomyolysis following quail consumption." Annals of Saudi medicine vol. 21,3 (2001): 219-20. doi: https://doi.org/10.5144/0256-4947.2001.219
Papanikolaou IS, Dourakis SP, Papadimitropoulos VS, Hadziyannis SJ. Acute rhabdomyolysis following quail consumption. Ann Saudi Med. 2001 May-Jul;21(3):219-20. doi: 10.5144/0256-4947.2001.219. PMID: 17264558.
Copy Download .nbib Format: NLM
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.

Hepatology international

Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR.
PMID: 23518903
Hepatol Int. 2013 Mar;7(1):88-97. doi: 10.1007/s12072-012-9343-x. Epub 2012 Mar 23.

PURPOSE: To investigate the durability of response to peginterferon alfa-2a up to 5 years post-treatment and factors associated with response in hepatitis B e-antigen (HBeAg)-negative patients.METHODS: HBeAg-negative patients received peginterferon alfa-2a (180 μg/week) ± lamivudine (100 mg/day) for 48...

Cite
Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2012;7(1):88-97doi: 10.1007/s12072-012-9343-x.
Marcellin, P., Bonino, F., Yurdaydin, C., Hadziyannis, S., Moucari, R., Kapprell, H. P., Rothe, V., Popescu, M., & Brunetto, M. R. (2013). Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatology international, 7(1), 88-97. https://doi.org/10.1007/s12072-012-9343-x
Marcellin, Patrick, et al. "Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients." Hepatology international vol. 7,1 (2013): 88-97. doi: https://doi.org/10.1007/s12072-012-9343-x
Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013 Mar;7(1):88-97. doi: 10.1007/s12072-012-9343-x. Epub 2012 Mar 23. PMID: 23518903; PMCID: PMC3601258.
Copy Download .nbib Format: NLM
Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.

World journal of hepatology

Rapti I, Hadziyannis S.
PMID: 26052395
World J Hepatol. 2015 May 18;7(8):1064-73. doi: 10.4254/wjh.v7.i8.1064.

Hepatocellular carcinoma (HCC) is a major health problem worldwide, representing one of the leading causes of death. Chronic hepatitis B virus (HBV) infection (CHB) is the most important etiologic factor of this tumor, accounting for the development of more...

Cite
Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol. 2015;7(8):1064-73doi: 10.4254/wjh.v7.i8.1064.
Rapti, I., & Hadziyannis, S. (2015). Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World journal of hepatology, 7(8), 1064-73. https://doi.org/10.4254/wjh.v7.i8.1064
Rapti, Irene, and Hadziyannis, Stephanos. "Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues." World journal of hepatology vol. 7,8 (2015): 1064-73. doi: https://doi.org/10.4254/wjh.v7.i8.1064
Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol. 2015 May 18;7(8):1064-73. doi: 10.4254/wjh.v7.i8.1064. PMID: 26052395; PMCID: PMC4450183.
Copy Download .nbib Format: NLM
An exploratory study of ascitic fluid lactate as prognostic factor of mortality in cirrhotic patients with spontaneous bacterial peritonitis.

European journal of gastroenterology & hepatology

Mani I, Alexopoulos T, Hadziyannis E, Tsiriga A, Vourli G, Alexopoulou A.
PMID: 34907985
Eur J Gastroenterol Hepatol. 2021 Dec 13; doi: 10.1097/MEG.0000000000002332. Epub 2021 Dec 13.

BACKGROUND: The diagnostic value of ascitic fluid lactate (AF lactate) was previously evaluated in spontaneous bacterial peritonitis (SBP) but its prognostic value was not established.AIM: To assess the prognostic value of AF lactate in SBP.METHODS: We prospectively studied 63...

Cite
Mani I, Alexopoulos T, Hadziyannis E, et al. An exploratory study of ascitic fluid lactate as prognostic factor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2021;doi: 10.1097/MEG.0000000000002332.
Mani, I., Alexopoulos, T., Hadziyannis, E., Tsiriga, A., Vourli, G., & Alexopoulou, A. (2021). An exploratory study of ascitic fluid lactate as prognostic factor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. European journal of gastroenterology & hepatology, . https://doi.org/10.1097/MEG.0000000000002332
Mani, Iliana, et al. "An exploratory study of ascitic fluid lactate as prognostic factor of mortality in cirrhotic patients with spontaneous bacterial peritonitis." European journal of gastroenterology & hepatology vol. (2021). doi: https://doi.org/10.1097/MEG.0000000000002332
Mani I, Alexopoulos T, Hadziyannis E, Tsiriga A, Vourli G, Alexopoulou A. An exploratory study of ascitic fluid lactate as prognostic factor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2021 Dec 13; doi: 10.1097/MEG.0000000000002332. Epub 2021 Dec 13. PMID: 34907985.
Copy Download .nbib Format: NLM
Evaluation of Two Methods for Quantitation of Hepatitis C Virus RNA.

Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology

Hadziyannis E, Fried MW, Nolte FS.
PMID: 10462590
Mol Diagn. 1997 Mar;2(1):39-46. doi: 10.1054/MODI00200039.

Background: Accurate quantitation of hepatitis C virus (HCV) RNA in serum may provide a means to predict disease course and response to interferon-alpha therapy. Several quantitative assays are commercially available, but none have been accepted as the gold standard....

Cite
Hadziyannis E, Fried MW, Nolte FS. Evaluation of Two Methods for Quantitation of Hepatitis C Virus RNA. Mol Diagn. 1997;2(1):39-46doi: 10.1054/MODI00200039.
Hadziyannis, E., Fried, M. W., & Nolte, F. S. (1997). Evaluation of Two Methods for Quantitation of Hepatitis C Virus RNA. Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology, 2(1), 39-46. https://doi.org/10.1054/MODI00200039
Hadziyannis, et al. "Evaluation of Two Methods for Quantitation of Hepatitis C Virus RNA." Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology vol. 2,1 (1997): 39-46. doi: https://doi.org/10.1054/MODI00200039
Hadziyannis E, Fried MW, Nolte FS. Evaluation of Two Methods for Quantitation of Hepatitis C Virus RNA. Mol Diagn. 1997 Mar;2(1):39-46. doi: 10.1054/MODI00200039. PMID: 10462590.
Copy Download .nbib Format: NLM
Viral Biomarkers in Chronic HBeAg Negative HBV Infection.

Genes

Hadziyannis E, Laras A.
PMID: 30262738
Genes (Basel). 2018 Sep 27;9(10). doi: 10.3390/genes9100469.

Viral biomarkers are important tools for monitoring chronic hepatitis B virus (HBV) hepatitis B early antigen (HBeAg) negative infection, both in its natural course as well as during and after treatment. The biomarkers consist of antibodies against viral epitopes,...

Cite
Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel). 2018;9(10)doi: 10.3390/genes9100469.
Hadziyannis, E., & Laras, A. (2018). Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes, 9(10), . https://doi.org/10.3390/genes9100469
Hadziyannis, Emilia, and Laras, Andreas. "Viral Biomarkers in Chronic HBeAg Negative HBV Infection." Genes vol. 9,10 (2018). doi: https://doi.org/10.3390/genes9100469
Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel). 2018 Sep 27;9(10). doi: 10.3390/genes9100469. PMID: 30262738; PMCID: PMC6210948.
Copy Download .nbib Format: NLM
Update on Hepatitis B Virus Infection: Focus on Treatment.

Journal of clinical and translational hepatology

Hadziyannis SJ.
PMID: 26355326
J Clin Transl Hepatol. 2014 Dec;2(4):285-91. doi: 10.14218/JCTH.2014.00026. Epub 2014 Dec 15.

This review article is an update of the current treatment strategies available for chronic hepatitis B. In addition to achieving on-therapy clinical remission and suppression of HBV replication without resistance, the ultimate goal of therapy is the development of...

Cite
Hadziyannis SJ. Update on Hepatitis B Virus Infection: Focus on Treatment. J Clin Transl Hepatol. 2014;2(4):285-91doi: 10.14218/JCTH.2014.00026.
Hadziyannis, S. J. (2014). Update on Hepatitis B Virus Infection: Focus on Treatment. Journal of clinical and translational hepatology, 2(4), 285-91. https://doi.org/10.14218/JCTH.2014.00026
Hadziyannis, Stephanos J. "Update on Hepatitis B Virus Infection: Focus on Treatment." Journal of clinical and translational hepatology vol. 2,4 (2014): 285-91. doi: https://doi.org/10.14218/JCTH.2014.00026
Hadziyannis SJ. Update on Hepatitis B Virus Infection: Focus on Treatment. J Clin Transl Hepatol. 2014 Dec;2(4):285-91. doi: 10.14218/JCTH.2014.00026. Epub 2014 Dec 15. PMID: 26355326; PMCID: PMC4521240.
Copy Download .nbib Format: NLM
Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy.

Annals of gastroenterology

Kotsiri I, Hadziyannis E, Georgiou A, Papageorgiou MV, Vlachogiannakos I, Papatheodoridis G.
PMID: 26752952
Ann Gastroenterol. 2016 Jan-Mar;29(1):79-84.

BACKGROUND: Several cytokines including transforming growth factor (TGF)-β1 have been suggested to be involved in the pathogenesis of fibrosis in chronic hepatitis C. We examined the changes of TGF-β1 serum levels and their predictive value in patients with chronic...

Cite
Kotsiri I, Hadziyannis E, Georgiou A, et al. Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy. Ann Gastroenterol. 2016;29(1):79-84
Kotsiri, I., Hadziyannis, E., Georgiou, A., Papageorgiou, M. V., Vlachogiannakos, I., & Papatheodoridis, G. (2016). Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy. Annals of gastroenterology, 29(1), 79-84.
Kotsiri, Ioanna, et al. "Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy." Annals of gastroenterology vol. 29,1 (2016): 79-84.
Kotsiri I, Hadziyannis E, Georgiou A, Papageorgiou MV, Vlachogiannakos I, Papatheodoridis G. Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy. Ann Gastroenterol. 2016 Jan-Mar;29(1):79-84. PMID: 26752952; PMCID: PMC4700851.
Copy Download .nbib Format: NLM
Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents.

Journal of viral hepatitis

Koutsianas C, Hadziyannis E, Thomas K, Deutsch M, Vassilopoulos D.
PMID: 34496105
J Viral Hepat. 2021 Dec;28(12):1710-1718. doi: 10.1111/jvh.13610. Epub 2021 Sep 20.

The effect of biologic treatment on quantitative Hepatitis B surface Antigen (qHBsAg) levels and HBsAg clearance in rheumatic patients with chronic HBV infection has not been well studied. We prospectively followed rheumatic patients with HBeAg-negative chronic HBV infection (n...

Cite
Koutsianas C, Hadziyannis E, Thomas K, et al. Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. J Viral Hepat. 2021;28(12):1710-1718doi: 10.1111/jvh.13610.
Koutsianas, C., Hadziyannis, E., Thomas, K., Deutsch, M., & Vassilopoulos, D. (2021). Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. Journal of viral hepatitis, 28(12), 1710-1718. https://doi.org/10.1111/jvh.13610
Koutsianas, Christos, et al. "Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents." Journal of viral hepatitis vol. 28,12 (2021): 1710-1718. doi: https://doi.org/10.1111/jvh.13610
Koutsianas C, Hadziyannis E, Thomas K, Deutsch M, Vassilopoulos D. Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. J Viral Hepat. 2021 Dec;28(12):1710-1718. doi: 10.1111/jvh.13610. Epub 2021 Sep 20. PMID: 34496105.
Copy Download .nbib Format: NLM
Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study.

Liver international : official journal of the International Association for the Study of the Liver

Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis GV.
PMID: 34890120
Liver Int. 2021 Dec 10; doi: 10.1111/liv.15128. Epub 2021 Dec 10.

BACKGROUND AND AIMS: Scarce data exist on the effect of nucleos(t)ide analogue (NA) discontinuation on hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe-). Therefore, we assessed whether HCC risk is increased in non-cirrhotic CHBe- patients who discontinue...

Cite
Papatheodoridi M, Su TH, Hadziyannis E, et al. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int. 2021;doi: 10.1111/liv.15128.
Papatheodoridi, M., Su, T. H., Hadziyannis, E., Liao, C. H., Orfanidou, �. �., Yang, H. C., Zachou, K., Liu, C. J., Kourikou, A., Gatselis, N., Manolakopoulos, S., Dalekos, G., Kao, J. H., Hadziyannis, S., & Papatheodoridis, G. V. (2021). Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver international : official journal of the International Association for the Study of the Liver, . https://doi.org/10.1111/liv.15128
Papatheodoridi, Margarita, et al. "Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study." Liver international : official journal of the International Association for the Study of the Liver vol. (2021). doi: https://doi.org/10.1111/liv.15128
Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis GV. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int. 2021 Dec 10; doi: 10.1111/liv.15128. Epub 2021 Dec 10. PMID: 34890120.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 29 entries